Phaseline

Companies › GT Medical Technologies

GT Medical Technologies: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 4, 1 Phase 3; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GammaTile (Cs-131 brachytherapy)
Cs-131 embedded in bioresorbable collagen tiles for focal brachytherapy
–Phase 4GlioblastomaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05342883GammaTile (Cs-131 brachytherapy)Phase 4GlioblastomaOncologyDec 2027
NCT07195591GammaTile (Cs-131 brachytherapy)Phase 3GlioblastomaOncologyDec 2031

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Lakefront Biotherapeutics Suzhou Immunofoco Biotechnology Biofrontera CG Oncology CNBG-Virogin Biotech (Shanghai)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.